In accordance with the target trial emulation framework, we first specified the protocol of a hypothetical randomized controlled trial (RCT) comparing the effects of initiating a GLP-1RA versus an SGLT2 inhibitor on the outcomes of AF/Aflutter and stroke among patients with T2D who have been receiving stable dose of levothyroxine
Hims, which offers both compounded and brand-name options, has navigated this more carefully than pure compounding platforms
Lipid-altering agents Approved agents for dyslipidemia Ezetimibe, a potent inhibitor of cholesterol absorption, has been explored for the treatment of NASH/NAFLD, but conflicting results exist [50,51,52]
NMDA receptor antagonists, such as memantine, are already in clinical use for the treatment of Alzheimer's disease, where they help reduce excitotoxic damage and improve cognitive function